Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy

Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few stu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alborz Rahmani, Guglielmo Dini, Andrea Orsi, Laura Sticchi, Bianca Bruzzone, Alfredo Montecucco, Luca Pellegrini, Alessia Manca, Alexander Domnich, Angela Battistini, Bruno Kusznir Vitturi, Sonia Zacconi, Nicoletta Debarbieri, Giancarlo Icardi, Paolo Durando
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 mRNA vaccine mass vaccination campaign occupational health healthcare workers reactogenicity Medicine R
Acceso en línea:	https://doaj.org/article/35a8cf0c45474c259c9b93047a78a45f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:35a8cf0c45474c259c9b93047a78a45f
record_format	dspace
spelling	oai:doaj.org-article:35a8cf0c45474c259c9b93047a78a45f2021-11-25T19:10:46ZReactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy10.3390/vaccines91112692076-393Xhttps://doaj.org/article/35a8cf0c45474c259c9b93047a78a45f2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1269https://doaj.org/toc/2076-393XVaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few studies have assessed its reactogenicity among the young working age population. An online survey was conducted to investigate the adverse reactions occurring in the 7 days following the first and second vaccination doses amongst resident doctors of the University of Genoa, employed at the IRCCS Ospedale Policlinico San Martino of Genoa, between 11 January and 16 March 2021. A total of 512 resident physicians were invited to participate in the study (female = 53.2%; mean age = 28.9 years), of whom 296 (female = 53.4%, mean age = 28.9 years) and 275 (female = 55.3%, mean age = 29.1 years) completed the survey after their first and second vaccination doses, respectively. In the 7 days following the first dose, most common adverse reactions were local pain (96.3%), fatigue (42.6%), headache (33.8%), arthromyalgia (28.0%), and 5.1% reported fever, while following the second dose, participants reported local pain (93.5%), fatigue (74.9%), headache (57.5%), arthromyalgia (58.2%), and fever (30.9%), with a higher prevalence among females. Systemic (but not local) reactions increased following the second vaccination, reaching severe intensity in 9.8% of participants and causing three or more events of moderate intensity in 23.7% of participants. Adverse reactions preventing regular daily activities could cause absenteeism among workers. These results can be useful to inform populations of young individuals, set expectations, and improve adherence to vaccination campaigns.Alborz RahmaniGuglielmo DiniAndrea OrsiLaura SticchiBianca BruzzoneAlfredo MontecuccoLuca PellegriniAlessia MancaAlexander DomnichAngela BattistiniBruno Kusznir VitturiSonia ZacconiNicoletta DebarbieriGiancarlo IcardiPaolo DurandoMDPI AGarticleCOVID-19mRNA vaccinemass vaccination campaignoccupational healthhealthcare workersreactogenicityMedicineRENVaccines, Vol 9, Iss 1269, p 1269 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 mRNA vaccine mass vaccination campaign occupational health healthcare workers reactogenicity Medicine R
spellingShingle	COVID-19 mRNA vaccine mass vaccination campaign occupational health healthcare workers reactogenicity Medicine R Alborz Rahmani Guglielmo Dini Andrea Orsi Laura Sticchi Bianca Bruzzone Alfredo Montecucco Luca Pellegrini Alessia Manca Alexander Domnich Angela Battistini Bruno Kusznir Vitturi Sonia Zacconi Nicoletta Debarbieri Giancarlo Icardi Paolo Durando Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
description	Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few studies have assessed its reactogenicity among the young working age population. An online survey was conducted to investigate the adverse reactions occurring in the 7 days following the first and second vaccination doses amongst resident doctors of the University of Genoa, employed at the IRCCS Ospedale Policlinico San Martino of Genoa, between 11 January and 16 March 2021. A total of 512 resident physicians were invited to participate in the study (female = 53.2%; mean age = 28.9 years), of whom 296 (female = 53.4%, mean age = 28.9 years) and 275 (female = 55.3%, mean age = 29.1 years) completed the survey after their first and second vaccination doses, respectively. In the 7 days following the first dose, most common adverse reactions were local pain (96.3%), fatigue (42.6%), headache (33.8%), arthromyalgia (28.0%), and 5.1% reported fever, while following the second dose, participants reported local pain (93.5%), fatigue (74.9%), headache (57.5%), arthromyalgia (58.2%), and fever (30.9%), with a higher prevalence among females. Systemic (but not local) reactions increased following the second vaccination, reaching severe intensity in 9.8% of participants and causing three or more events of moderate intensity in 23.7% of participants. Adverse reactions preventing regular daily activities could cause absenteeism among workers. These results can be useful to inform populations of young individuals, set expectations, and improve adherence to vaccination campaigns.
format	article
author	Alborz Rahmani Guglielmo Dini Andrea Orsi Laura Sticchi Bianca Bruzzone Alfredo Montecucco Luca Pellegrini Alessia Manca Alexander Domnich Angela Battistini Bruno Kusznir Vitturi Sonia Zacconi Nicoletta Debarbieri Giancarlo Icardi Paolo Durando
author_facet	Alborz Rahmani Guglielmo Dini Andrea Orsi Laura Sticchi Bianca Bruzzone Alfredo Montecucco Luca Pellegrini Alessia Manca Alexander Domnich Angela Battistini Bruno Kusznir Vitturi Sonia Zacconi Nicoletta Debarbieri Giancarlo Icardi Paolo Durando
author_sort	Alborz Rahmani
title	Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title_short	Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title_full	Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title_fullStr	Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title_full_unstemmed	Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title_sort	reactogenicity of bnt162b2 mrna covid-19 vaccine in a young working age population: a survey among medical school residents, within a mass vaccination campaign, in a regional reference teaching hospital in italy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/35a8cf0c45474c259c9b93047a78a45f
work_keys_str_mv	AT alborzrahmani reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT guglielmodini reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT andreaorsi reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT laurasticchi reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT biancabruzzone reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT alfredomontecucco reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT lucapellegrini reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT alessiamanca reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT alexanderdomnich reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT angelabattistini reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT brunokusznirvitturi reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT soniazacconi reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT nicolettadebarbieri reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT giancarloicardi reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly AT paolodurando reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
_version_	1718410207334236160

Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy

Ejemplares similares